The IPO stock has more than tripled in under a year as investors watch its efforts to take on Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ). The New York-based company has one drug: an oral formulation of the antipsychotic benzamide. It calls the drug LB-102.
Benzamide is approved in…
Extract — continue reading at the source.
Related stories
Home-insurance premiums just hit a record high. Here’s where they spiked the most.
Hunter Biden’s memecoin flops, falling 95% just hours after launch
LIV races to re-sign golfers to clinch $300mn bankruptcy rescue
Drone almost struck Zelenskyy’s plane, says Ukraine
The bull market’s biggest enemy right now could be Bessent’s interventions
Hunter Biden’s $LAPTOP memecoin crashes shortly after launch